北美药代动力学服务市场预测至 2031 年 - 区域分析 - 按药物类型（小分子、大分子和疫苗）、服务类型（临床前 ADME 和人体研究、PK/PD 分析和报告、剂量模拟、风险分析等）、治疗应用（肿瘤学、传染病、神经系统疾病、自身免疫性疾病、妇科疾病、心血管疾病、呼吸系统疾病等）和最终用户（制药和生物技术公司、合同研究组织等）
药代动力学研究应用范围不断扩大，推动北美药代动力学服务市场发展
药代动力学研究用于确定几个参数，例如人体等效剂量 (HED) 水平、未观察到效应水平 (NOEL) 和药代动力学/药效学测试。进行的任何临床前项目的主要重点是支持对药代动力学研究中测试的安全有效剂量范围的分析。几项毒理学研究对 NOEL 进行了数据处理，即不会产生不良影响的最高剂量。如果缺乏临床药代动力学数据，则根据比较体表面积将该剂量水平进一步转换为 HED 水平。了解潜在候选药物的药代动力学特征在药物发现计划中起着重要作用。监管机构在推动药代动力学研究的实施方面发挥着重要作用。这些研究还有助于优化为住院患者提供的药物护理服务。PK 模型通常用于确定药物暴露量、药物浓度以分析最佳剂量，并分析药物在人体内的分布。医疗保健提供者实施 PK 原理来设计监测药物浓度、某些药物的剂量，最大限度地实现预期的治疗效果并最大限度地降低毒性。
北美药代动力学服务市场概览
美国在北美药代动力学服务市场中占有最大份额。该国已成为领先的临床研究目的地；它占全球临床试验总数的约 50%。完善的医疗基础设施、快速的审批流程和有利的监管框架为制药研究公司开展临床试验创造了有利环境。此外，在美国进行的试验产生的数据在全球范围内得到认可。根据世界卫生组织 (WHO) 的报告，美国在 2021 年登记的临床试验数量最多 (157,618)。
北美药代动力学服务市场收入和预测到 2031 年（百万美元）
北美药代动力学服务市场细分
北美药代动力学服务市场分为药物类型、服务类型、治疗应用、最终用户和国家。
根据药物类型，北美药代动力学服务市场分为小分子、大分子和疫苗。小分子细分市场在 2023 年占据最大市场份额。
就服务类型而言，北美药代动力学服务市场分为临床前 ADME 和人体研究、PK/PD 分析和报告、剂量模拟、风险分析等。临床前 ADME 和人体研究细分市场在 2023 年占据最大市场份额。
按治疗应用，北美药代动力学服务市场细分为肿瘤学、传染病、神经系统疾病、自身免疫性疾病、妇科疾病、心血管疾病、呼吸系统疾病等。肿瘤学细分市场在 2023 年占据最大市场份额。
按最终用户，北美药代动力学服务市场细分为制药和生物技术公司、合同研究组织等。合同研究组织部门在 2023 年占据了最大的市场份额。
按国家/地区划分，北美药代动力学服务市场分为美国、加拿大和墨西哥。2023 年，美国占据了北美药代动力学服务市场份额的主导地位。
Charles River Laboratories International Inc；Eurofins Scientific SE；Evotec SE；Certara Inc.；Parexel International Corp；Thermo Fisher Scientific Inc.；Allucent；PACIFIC BIOLABS；和 SGS SA 是北美药代动力学服务市场的一些领先公司。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Pharmacokinetics Services Market Landscape
4.1 PEST Analysis
5. North America Pharmacokinetics Services Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Chronic and Infectious Diseases
5.1.2 Expanding Range of Application of Pharmacokinetic Studies
5.1.3 Outsourcing of Pharmacokinetics Services to CROs
5.2 Market Restraints
5.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
5.3 Market Opportunities
5.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
5.4 Future Trend
5.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
5.5 Impact of Drivers and Restraints:
6. Pharmacokinetics Services Market - North America Analysis
6.1 North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
7. North America Pharmacokinetics Services Market Analysis - by Drug Type
7.1 Overview
7.2 Small Molecule
7.2.1 Overview
7.2.2 Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Large Molecule
7.3.1 Overview
7.3.2 Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Vaccines
7.4.1 Overview
7.4.2 Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. North America Pharmacokinetics Services Market Analysis - by Service Type
8.1 Overview
8.2 Pre-Clinical ADME and Human Studies
8.2.1 Overview
8.2.2 Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 PK/PD Analysis and Reporting
8.3.1 Overview
8.3.2 PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Dosing Simulations
8.4.1 Overview
8.4.2 Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Risk Analysis
8.5.1 Overview
8.5.2 Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. North America Pharmacokinetics Services Market Analysis - by Therapeutic Application
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Infectious Diseases
9.2.1 Overview
9.2.2 Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Neurological Disorders
9.3.1 Overview
9.3.2 Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Autoimmune Diseases
9.4.1 Overview
9.4.2 Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.5 Gynecological Disorders
9.5.1 Overview
9.5.2 Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.6 Cardiovascular Diseases
9.6.1 Overview
9.6.2 Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.7 Respiratory Disorders
9.7.1 Overview
9.7.2 Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. North America Pharmacokinetics Services Market Analysis - by End User
10.1 Pharmaceutical and Biotechnology Companies
10.1.1 Overview
10.1.2 Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Contract Research Organization
10.2.1 Overview
10.2.2 Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Others
10.3.1 Overview
10.3.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11. North America Pharmacokinetics Services Market - Country Analysis
11.1 North America
11.1.1 North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
11.1.1.1 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.1.3 United States: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.1.4 United States: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.1.5 United States: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.1.6 United States: North America Pharmacokinetics Services Market Breakdown, by End User
11.1.1.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.2.3 Canada: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.2.4 Canada: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.2.5 Canada: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.2.6 Canada: North America Pharmacokinetics Services Market Breakdown, by End User
11.1.1.3 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.3.3 Mexico: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.3.4 Mexico: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.3.5 Mexico: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.3.6 Mexico: North America Pharmacokinetics Services Market Breakdown, by End User
12. Company Profile
12.1 Charles River Laboratories International Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Eurofins Scientific SE
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Evotec SE
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Certara Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.5 Parexel International Corp
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Allucent
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 PACIFIC BIOLABS
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 SGS SA
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms for Pharmacokinetic Services Market
List of Tables
Table 1. North America Pharmacokinetics Services Market Segmentation
Table 2. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 3. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 4. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 5. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 6. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 7. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 8. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 9. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 10. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 11. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 12. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 13. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 14. Glossary of Terms
List of Figures
Figure 1. North America Pharmacokinetics Services Market Segmentation, by Country
Figure 2. PEST Analysis
Figure 3. North America Pharmacokinetics Services Market - Key Market Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 6. North America Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
Figure 7. Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 10. North America Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
Figure 11. Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 16. North America Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
Figure 17. Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 25. North America Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
Figure 26. Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 29. North America Pharmacokinetics Services Market by Key Countries - Revenue (2023) (US$ Million)
Figure 30. North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 31. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 32. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
Figure 33. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- Evotec SE
- Certara Inc.
- Parexel International Corp
- Thermo Fisher Scientific Inc.
- Allucent
- PACIFIC BIOLABS
- SGS SA
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America pharmacokinetics services market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America pharmacokinetics services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.